Quantifying bile acid malabsorption helps predict response and tailor sequestrant therapy

59Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Although recognised as a cause of chronic diarrhoea for over forty years, diagnostic tests and treatments for bile acid malabsorption (BAM) remain controversial. Recent National Institute for Health and Care Excellence (NICE) guidelines highlighted the lack of evidence in the field, and called for further research. This retrospective study explores the BAM subtype and severity, the use and response to bile acid sequestrants (BAS) and the prevalence of abnormal colonic histology. 264 selenium-75-labelled homocholic acid conjugated taurine (SeHCAT)-tested patient records were reviewed and the severity and subtype of BAM, presence of colonic histopathology and response to BAS were recorded. 53% of patients tested had BAM, with type-2 BAM in 45% of patients with presumed irritable bowel syndrome. Colonic histological abnormalities were similar overall between patients with (29%) or without (23%) BAM (p=0.46) and between BAM subtypes, with no significant presence of inflammatory changes. 63% of patients with BAM had a successful BAS response which showed a trend to decreased response with reduced severity. Colestyramine was unsuccessful in 44% (38/87) and 45% of these (17/38) were related to medication intolerance, despite a positive SeHCAT. 47% (7/15) of colestyramine failures had a successful colesevelam response. No patient reported colesevelam intolerance. Quantifying severity of BAM appears to be useful in predicting BAS response. Colesevelam was better tolerated than colestyramine and showed some efficacy in colestyramine failures. Colestyramine failure should not be used to exclude BAM. Colonic histology is of no relevance.

References Powered by Scopus

Systematic review: The prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome

360Citations
N/AReaders
Get full text

A New Mechanism for Bile Acid Diarrhea: Defective Feedback Inhibition of Bile Acid Biosynthesis

275Citations
N/AReaders
Get full text

The Syndrome of Ileal Disease and the Broken Enterohepatic Circulation: Cholerheic Enteropathy

222Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Irritable bowel syndrome

486Citations
N/AReaders
Get full text

British Society of Gastroenterology guidelines on the management of irritable bowel syndrome

301Citations
N/AReaders
Get full text

Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition

236Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Orekoya, O., McLaughlin, J., Leitao, E., Johns, W., Lal, S., & Paine, P. (2015). Quantifying bile acid malabsorption helps predict response and tailor sequestrant therapy. Clinical Medicine, Journal of the Royal College of Physicians of London, 15(3), 252–257. https://doi.org/10.7861/clinmedicine.15-3-252

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 10

56%

Researcher 5

28%

Professor / Associate Prof. 3

17%

Readers' Discipline

Tooltip

Medicine and Dentistry 19

83%

Business, Management and Accounting 2

9%

Materials Science 1

4%

Arts and Humanities 1

4%

Article Metrics

Tooltip
Mentions
News Mentions: 2

Save time finding and organizing research with Mendeley

Sign up for free